Chen Cheng1,2, Jia-zhen Lin1,3, Li Li1, Jun-ling Yang1, Wei-wei Jia1, Yu-hong Huang4, Fei-fei Du1, Feng-qing Wang1, Mei-juan Li1, Yan-fen Li4, Fang Xu1, Na-ting Zhang1, Olajide E Olaleye1, Yan Sun1,5, Jian Li1, Chang-hai Sun6, Gui-ping Zhang6, Chuan Li1,2,3. 1. Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China. 2. Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China. 3. University of Chinese Academy of Sciences, Shanghai 201203, China. 4. Second Affiliated Hospital, Tianjin University of Traditional Chinese Medicine, Tianjin 300150, China. 5. Now in Laboratory of Phase I Clinical Trials, Fudan University Shanghai Cancer Center, Shanghai 200032, China. 6. Tianjin Chasesun Pharmaceutical Co, Ltd, Tianjin 301700, China.
Abstract
AIM: Monoterpene glycosides derived from Paeonia lactiflora roots (Chishao) are believed to be pharmacologically important for the antiseptic herbal injection XueBiJing. This study was designed to characterize the pharmacokinetics and disposition of monoterpene glycosides. METHODS: Systemic exposure to Chishao monoterpene glycosides was assessed in human subjects receiving anintravenous infusion and multiple infusions of XueBiJing injection, followed by assessment of the pharmacokinetics of the major circulating compounds. Supportive rat studies were also performed. Membrane permeability and plasma-protein binding were assessed in vitro. RESULTS: A total of 18 monoterpene glycosides were detected in XueBiJing injection (content levels, 0.001-2.47 mmol/L), and paeoniflorin accounted for 85.5% of the total dose of monoterpene glycosides detected. In human subjects, unchanged paeoniflorin exhibited considerable levels of systemic exposure with elimination half-lives of 1.2-1.3 h; no significant metabolite was detected. Oxypaeoniflorin and albiflorin exhibited low exposure levels, and the remaining minor monoterpene glycosides were negligible or undetected. Glomerular-filtration-based renal excretion was the major elimination pathway of paeoniflorin, which was poorly bound to plasma protein. In rats, the systemic exposure level of paeoniflorin increased proportionally as the dose was increased. Rat lung, heart, and liver exposure levels of paeoniflorin were lower than the plasma level, with the exception of the kidney level, which was 4.3-fold greater than the plasma level; brain penetration was limited by the poor membrane permeability. CONCLUSION: Due to its significant systemic exposure and appropriate pharmacokinetic profile, as well as previously reported antiseptic properties, paeoniflorin is a promising XueBiJing constituent of therapeutic importance.
RCT Entities:
AIM: Monoterpene glycosides derived from Paeonia lactiflora roots (Chishao) are believed to be pharmacologically important for the antiseptic herbal injection XueBiJing. This study was designed to characterize the pharmacokinetics and disposition of monoterpene glycosides. METHODS: Systemic exposure to Chishao monoterpene glycosides was assessed in human subjects receiving an intravenous infusion and multiple infusions of XueBiJing injection, followed by assessment of the pharmacokinetics of the major circulating compounds. Supportive rat studies were also performed. Membrane permeability and plasma-protein binding were assessed in vitro. RESULTS: A total of 18 monoterpene glycosides were detected in XueBiJing injection (content levels, 0.001-2.47 mmol/L), and paeoniflorin accounted for 85.5% of the total dose of monoterpene glycosides detected. In human subjects, unchanged paeoniflorin exhibited considerable levels of systemic exposure with elimination half-lives of 1.2-1.3 h; no significant metabolite was detected. Oxypaeoniflorin and albiflorin exhibited low exposure levels, and the remaining minor monoterpene glycosides were negligible or undetected. Glomerular-filtration-based renal excretion was the major elimination pathway of paeoniflorin, which was poorly bound to plasma protein. In rats, the systemic exposure level of paeoniflorin increased proportionally as the dose was increased. Rat lung, heart, and liver exposure levels of paeoniflorin were lower than the plasma level, with the exception of the kidney level, which was 4.3-fold greater than the plasma level; brain penetration was limited by the poor membrane permeability. CONCLUSION: Due to its significant systemic exposure and appropriate pharmacokinetic profile, as well as previously reported antiseptic properties, paeoniflorin is a promising XueBiJing constituent of therapeutic importance.
Authors: Hernando Gomez; Can Ince; Daniel De Backer; Peter Pickkers; Didier Payen; John Hotchkiss; John A Kellum Journal: Shock Date: 2014-01 Impact factor: 3.454
Authors: Y Z Shu; M Hattori; T Akao; K Kobashi; K Kagei; K Fukuyama; T Tsukihara; T Namba Journal: Chem Pharm Bull (Tokyo) Date: 1987-09 Impact factor: 1.645
Authors: Feng Jiao; Kevin Varghese; Shaoxun Wang; Yedan Liu; Hongwei Yu; George W Booz; Richard J Roman; Ruen Liu; Fan Fan Journal: J Cardiovasc Pharmacol Date: 2021-06-01 Impact factor: 3.271